Clinician perceptions of research priorities for the management of noncritically ill patients admitted to hospital with SARS-CoV-2 infection
© 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians..
The changing phenotype of coronarvirus disease 2019 (COVID-19) may quickly render guideline-recommended interventions obsolete. We developed a 40-question clinician survey in consultation with the Australasian COVID-19 Trial site investigators. The survey was designed to assess clinician perceptions of the current treatment strategies and future research priorities in the management of non-critically ill patients admitted to hospital with SARS-CoV-2 infection. There were 84 complete responses from predominantly Australian and New Zealand clinicians. The perceived prevalence of patients with incidental COVID-19, nosocomial infection, underlying illness exacerbated by COVID-19, and/or immunocompromised status suggests new populations to target. The results highlighted clinician interest in antiviral therapies for future research in both immunocompetent and immunocompromised cohorts. These survey results underscore the need for ongoing surveillance of COVID-19 disease phenotypes and clinician and patient priorities for future research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Internal medicine journal - 54(2024), 2 vom: 11. Feb., Seite 337-341 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bandara, Methma M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.02.2024 Date Revised 15.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/imj.16316 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368407667 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368407667 | ||
| 003 | DE-627 | ||
| 005 | 20240215232108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/imj.16316 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM368407667 | ||
| 035 | |a (NLM)38350659 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bandara, Methma M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinician perceptions of research priorities for the management of noncritically ill patients admitted to hospital with SARS-CoV-2 infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2024 | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. | ||
| 520 | |a The changing phenotype of coronarvirus disease 2019 (COVID-19) may quickly render guideline-recommended interventions obsolete. We developed a 40-question clinician survey in consultation with the Australasian COVID-19 Trial site investigators. The survey was designed to assess clinician perceptions of the current treatment strategies and future research priorities in the management of non-critically ill patients admitted to hospital with SARS-CoV-2 infection. There were 84 complete responses from predominantly Australian and New Zealand clinicians. The perceived prevalence of patients with incidental COVID-19, nosocomial infection, underlying illness exacerbated by COVID-19, and/or immunocompromised status suggests new populations to target. The results highlighted clinician interest in antiviral therapies for future research in both immunocompetent and immunocompromised cohorts. These survey results underscore the need for ongoing surveillance of COVID-19 disease phenotypes and clinician and patient priorities for future research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a immunocompromised | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Barina, Lauren A |e verfasserin |4 aut | |
| 700 | 1 | |a McPhee, Grace M |e verfasserin |4 aut | |
| 700 | 1 | |a Goulding, Susan R |e verfasserin |4 aut | |
| 700 | 1 | |a Denholm, Justin T |e verfasserin |4 aut | |
| 700 | 1 | |a Morpeth, Susan C |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Steven Y C |e verfasserin |4 aut | |
| 700 | 0 | |a ASCOT Group |e verfasserin |4 aut | |
| 700 | 1 | |a Basnet, Bhupendra K |e investigator |4 oth | |
| 700 | 1 | |a Bowen, Asha C |e investigator |4 oth | |
| 700 | 1 | |a Hammond, Naomi E |e investigator |4 oth | |
| 700 | 1 | |a Jha, Vivekanand |e investigator |4 oth | |
| 700 | 1 | |a Jones, Mark |e investigator |4 oth | |
| 700 | 1 | |a McQuilten, Zoe K |e investigator |4 oth | |
| 700 | 1 | |a Mora, Jocelyn M |e investigator |4 oth | |
| 700 | 1 | |a Nguyen, Vi |e investigator |4 oth | |
| 700 | 1 | |a O'Sullivan, Matthew V N |e investigator |4 oth | |
| 700 | 1 | |a Paterson, David L |e investigator |4 oth | |
| 700 | 1 | |a Price, David J |e investigator |4 oth | |
| 700 | 1 | |a Rees, Megan A |e investigator |4 oth | |
| 700 | 1 | |a Snelling, Thomas L |e investigator |4 oth | |
| 700 | 1 | |a Trask, Nanette T |e investigator |4 oth | |
| 700 | 1 | |a Davis, Joshua S |e investigator |4 oth | |
| 700 | 1 | |a Roberts, Jason A |e investigator |4 oth | |
| 700 | 1 | |a Venkatesh, Balasubramanian |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine journal |d 2001 |g 54(2024), 2 vom: 11. Feb., Seite 337-341 |w (DE-627)NLM113582811 |x 1445-5994 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:2 |g day:11 |g month:02 |g pages:337-341 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/imj.16316 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2024 |e 2 |b 11 |c 02 |h 337-341 | ||